Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
We didn't hear anything from Flatlander, very strange. Hope he's doing well.
Thole schreef op 26 februari 2022 08:51 :
We didn't hear anything from Flatlander, very strange. Hope he's doing well.
He sold and gave up.
DeZwarteRidder schreef op 26 februari 2022 08:52 :
[...]
He sold and gave up.
Maybe, maybe not. We will hear it from him.
I'm still around. It has been a rough week. My heritage is half Ukrainian. While I do not speak the language I feel that their plight is the only thing that matters in the world right now. My BCART position is about half of what it was at the peak and it has never been more than a couple percent of my overall holdings. I find it especially disappointing that for the 2nd time in 3 years that Verrelst has announced another restructuring of the U.S. operations. Verrelst has gotten way ahead of himself be overextending the personnel in the U.S. before securing IVD 510K registrations for any oncology assays. As I have said on numerous occasions, the RUO market is less than 10% of the total MDx market in the U.S. There is a reason that sales growth is strongest in the EU and the ROW since that is where assays have been approved for IVD use. Spending a disproportionately in the U.S. ahead of such approvals is a major problem given the current cash position. I find that this scenario offers a silver lining. If registration approvals allow the sales growth rate to push into 60% range, then there is hope that this is a surmountable problem if BCART can survive independently for the next couple years. The PR indicates that much of the cost associated with ML3 has been incurred, yet the registrations will not be received until late 2023. So there will not be a return on that investment more several years. Again this might be seen as a misallocation of limited resources. I'll give them a pass on this one since it sounds like the Chinese changed the requirements in midcourse. BCART needs to determine whether the Chinese are throwing up roadblocks to protect entrenched competitors. I agree with OzDx's comment about this being an industry where it is tough to gain traction but once entrenched there can be a decades long trajectory of 20+ growth, ala the Cepheid example. I no longer support the notion that every dip is an opportunity to pick up more shares. Quite simply, BCART needs to demonstrate the path to profitability and needs to show they will secure funds maintain continuing operations. You'll have to excuse the limited number of posts. The world is being threatened by a madman and BCART is much further down the list of concerns at the moment. FL
FL, all the best for you and your family, and hopefully there soon will come an end to this madness.
El Torro I have never even met my 2nd and 3rd cousins in the Ukraine, yet like most of the world I feel their plight deeply. As I write this, kharkiv is under a massive assault. Many civilians are being killed. This is likely a ploy by the Russians to keep the pressure up going into the negotiations. I believe the Ukrainians will offer a promise not to join NATO, so that Putin can save face and claim a victory. However the world knows that what he really wanted was to install a puppet government, so Ukraine not joining NATO would not be a victory for Russia, Putin is weakened by this and hopefully it stirs action to replace him. The war was ill conceived. The captured Russian soldiers cannot even put into words the reason why they are in the Ukraine fighting. Contrast that with Ukrainians fighting for their homeland. No one will ever hold it against the Ukrainians if they renege on any peace condition agreements in the distant future. How many times in the past has Putin lied. FL
FL, These events have really shook up Europe in a way we never could have expected. At this moment already 500.000 women and children have entered the EU for shelter and more to come. There's a massive solidarity among the European population for the people of Ukraine. He miscalculated that he could conquer Kiev with a blitz offensive and install a puppet regime quickly. But the resistance is very tough and in the whole country Ukrainian men are picking up arms and are mobilizing to fight with the armed forces. I'm afraid this could go on for some time, with the biggest victims: the citizens of a country that just wanted to be a part of Europe.
Ukraine's history has been one chapter after the next of abuse at the hands of the Russians despite Putin referring to the Ukraine as their Slavic brothers. The Ukrainians are a tough people. The Stalin induced starvation or Holodomor killed an estimated 3.5 million in 1932 and 1933 and now this blatant attack. Even if the Ukrainian military fails and ceases to fight as a unit, Putin will have a gorilla war that will kill many occupiers for as long as they remain. My fear is that Putin cannot accept his overreach. His soldiers do not want to conduct building to building warfare so I fear that he will turn this into an Aleppo Syria by indiscriminately bombing civilian areas. The Western response has been strong but the threat of a nuclear war with a madman is weighing on all of us. I'm hopeful that the ban on all semiconductor sales to Russia gains support. Unfortunately, this would likely require China's assistance. Russians should live in the stone age as retribution for their naked aggression. If there is a positive side of all of this, is that politicians and news media in the U.S. that have supported or provided cover for Putin are being called out and isolated. FL
Advies van Bryan Garnier over Biocartis Beurshuis Bryan Garnier Aandeel Biocartis Group Datum 02 maart 2022 Advies Neutraal Koersdoel 2,50 EUR Detail advies (Trivano.com) - Op 2 maart 2022 brengen de analisten van Bryan Garnier het beleggingsadvies "neutraal" uit voor Biocartis Group (BCART; ISIN: BE0974281132). Het koersdoel wordt door de analisten vastgelegd op 2,50 EUR. Op 24 februari 2022 publiceerde Biocartis Group zijn jaarresultaten.
Gazet van Antwerpen zaterdag 26 februari.epaper.gva.be/data/2225/reader/reader...
Link werkt blijkbaar niet, hier de tekst. Beurstips Kopen Biocartis, een Mechels bedrijf dat onderzoek doet naar de verwekkers van kanker en er daardoor voor kan zorgen dat de patiënt een betere behandeling krijgt, zag zijn inkomsten vorig jaar fors stijgen. Ook de winstmarges gaan naar omhoog. De beleggingsspecialisten van KBC Securuties wijzen onder meer op de stijging van de gemiddelde verkoopsprijzen, die extra winst met zich meebrengt. KBC raad je aan om aandelen van Biocartis te kopen. Een aandeel kost 2,5 euro. Einde tekst uit gazet van Antwerpen. Ondertussen koers op 2,28 euro Zo zie je maar, met analisten kun ge alle kanten uit.
KBC Securities geeft een koersdoel van 7€ voor Biocartis op lange termijn ,maar daar heb ik mijn twijfels over ,aangezien KBC de huisbankier is van biocartis.
Ik vermoed dat Biocartis zal wegzakken onder de 2 EUR. Rond 1.5 EUR durf ik opnieuw instappen.
Wright's Law Verrelst emphasized that this year will be important as BCART scales up production to reduce costs. In my mind, this was precisely the right note to hit. A few months ago, I started a thread here about Cathy Wood's discussion of Ark looking for companies that had completed the innovation phase and were entering the scaling phase. She talked about applying Wright's Law to these companies. She mentioned that for robotics and health care companies she estimates that for each doubling in product output the fixed cost of production are reduced by approximately 25 to 30%. I was looking for evidence of Wright's Law occurring when the fire struck. I maintain that BCART should be bought when and if they show that the scaling is paving the way to profitability. FL
www.forbes.com/sites/arielcohen/2022/... If the west can curtail the flow of semiconductors from Taiwan and Singapore the Russian military machine will grind to a halt. It won't be instantaneous but it will be effective over the long run, FL
Inside information: Diverse hooggeschoolde externe medewerkers bij Biocartis hebben hun ontslag gekregen, met de bekende , te verwachten uitleg van de baas. Ze mogen tot 31 maart daar blijven werken en dan is het over en uit. For Flatlander: Some high qualified team-members are dismissed per 31 March 2022. Peter
Welkom terug Peter. Nu Josti5 (John) nog.
ffff schreef op 2 maart 2022 15:17 :
Inside information:
Diverse hooggeschoolde externe medewerkers bij Biocartis hebben hun ontslag gekregen, met de bekende , te verwachten uitleg van de baas. Ze mogen tot 31 maart daar blijven werken en dan is het over en uit.
For Flatlander: Some high qualified team-members are dismissed per 31 March 2022.
Peter
Inderdaad, ook enkele kennissen van mij die daar als freelancer werken, mogen binnenkort opkrassen. Joshua Andrade
ffff schreef op 2 maart 2022 15:17 :
Inside information:
Diverse hooggeschoolde externe medewerkers bij Biocartis hebben hun ontslag gekregen, met de bekende , te verwachten uitleg van de baas. Ze mogen tot 31 maart daar blijven werken en dan is het over en uit.
For Flatlander: Some high qualified team-members are dismissed per 31 March 2022.
Peter
En welke uitleg is dat dan?
Uitleg?Ze voldoen niet?Na de brand vorige zomer extra aanwervingen om productie achterstand in te halen?Ze veranderen van Startup naar een bedrijf die de productie wil opdrijven, waarschijnlijk hebben ze andere profielen nodig?De persoon die de FDA approvals of CE goedkeuringen klasseert zit er ook werkloos bij?De persoon die het geld in kas telt is ook elke dag sneller klaar?....De huidige situatie laat niet toe dat er overbodig personeel betaald moet worden.Misschien rekken ze het hierdoor nog enkele maanden langer.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee